William G. Bornmann

18.3k total citations · 6 hit papers
167 papers, 14.7k citations indexed

About

William G. Bornmann is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, William G. Bornmann has authored 167 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Molecular Biology, 49 papers in Oncology and 41 papers in Organic Chemistry. Recurrent topics in William G. Bornmann's work include Chronic Myeloid Leukemia Treatments (32 papers), Cancer therapeutics and mechanisms (22 papers) and Chronic Lymphocytic Leukemia Research (19 papers). William G. Bornmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (32 papers), Cancer therapeutics and mechanisms (22 papers) and Chronic Lymphocytic Leukemia Research (19 papers). William G. Bornmann collaborates with scholars based in United States, Russia and France. William G. Bornmann's co-authors include John Kuriyan, Bayard Clarkson, Thomas H. Schindler, Darren R. Veach, W. Todd Miller, Patricia Pellicena, Bhushan Nagar, Martin E. Kuehne, David A. Boothman and Samuel J. Danishefsky and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

William G. Bornmann

167 papers receiving 14.2k citations

Hit Papers

Structural Mechanism for ... 1997 2026 2006 2016 2000 2002 2003 2009 2007 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
    2000 1.4k citations William G. Bornmann et al. profile →
  2. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
    2002 731 citations William G. Bornmann et al. PubMed profile →
  3. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
    2003 654 citations William G. Bornmann et al. profile →
  4. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
    2009 552 citations Ismael Samudio, Marina Konopleva et al. Journal of Clinical Investigation profile →
  5. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    2007 535 citations William G. Bornmann, Jacqueline Bromberg et al. Journal of Clinical Investigation profile →
  6. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
    1997 530 citations William G. Bornmann et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
William G. Bornmann 7.7k 3.6k 2.9k 2.7k 1.8k 167 14.7k
Charles Dumontet 9.2k 1.2× 8.6k 2.4× 2.2k 0.8× 2.2k 0.8× 1.8k 1.0× 377 20.7k
Steven Grant 16.7k 2.2× 6.3k 1.7× 1.2k 0.4× 3.6k 1.3× 1.7k 0.9× 451 23.2k
Edward A. Sausville 19.3k 2.5× 11.7k 3.2× 2.7k 0.9× 2.1k 0.8× 1.7k 1.0× 329 30.9k
Lorenzo A. Pinna 15.9k 2.1× 3.4k 0.9× 1.3k 0.5× 1.1k 0.4× 1.5k 0.8× 448 21.6k
Robert Roskoski 9.9k 1.3× 4.1k 1.1× 1.6k 0.6× 862 0.3× 1.1k 0.6× 173 16.3k
Stefan Knapp 21.6k 2.8× 5.6k 1.5× 3.7k 1.3× 3.9k 1.4× 827 0.5× 516 29.0k
E. Premkumar Reddy 10.4k 1.4× 4.8k 1.3× 1.0k 0.3× 1.5k 0.5× 1.1k 0.6× 203 17.2k
Thomas Meyer 3.7k 0.5× 2.2k 0.6× 1.2k 0.4× 1.5k 0.6× 961 0.5× 137 7.9k
Aviv Gazit 5.3k 0.7× 3.3k 0.9× 1.1k 0.4× 1.0k 0.4× 920 0.5× 99 9.7k
Giulio Superti‐Furga 13.5k 1.8× 2.9k 0.8× 1.1k 0.4× 3.1k 1.2× 2.1k 1.2× 247 21.7k

Countries citing papers authored by William G. Bornmann

Since Specialization
Citations

This map shows the geographic impact of William G. Bornmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Bornmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Bornmann more than expected).

Fields of papers citing papers by William G. Bornmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William G. Bornmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Bornmann. The network helps show where William G. Bornmann may publish in the future.

Co-authorship network of co-authors of William G. Bornmann

This figure shows the co-authorship network connecting the top 25 collaborators of William G. Bornmann. A scholar is included among the top collaborators of William G. Bornmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William G. Bornmann. William G. Bornmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Long-Shan, Shuangping Liu, Hyunsil Park, et al.. (2016). NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Molecular Cancer Therapeutics. 15(7). 1757–1767. 45 indexed citations
2.
Zhang, Weiguo, Vivian Ruvolo, Gao Chen, et al.. (2014). Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(7). 1848–1859. 30 indexed citations
3.
Cao, Lifen, Long Shan Li, Ling Xiao, et al.. (2014). Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers. Antioxidants and Redox Signaling. 21(2). 237–250. 32 indexed citations
4.
Bey, Erik A., Kathryn E. Reinicke, Melissa C. Srougi, et al.. (2013). Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers. Molecular Cancer Therapeutics. 12(10). 2110–2120. 84 indexed citations
5.
Arumugam, Thiruvengadam, Vijaya Ramachandran, Duoli Sun, et al.. (2013). Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy. Molecular Cancer Therapeutics. 12(5). 654–662. 41 indexed citations
6.
Dai, Bingbing, Jieru Meng, Michael Peyton, et al.. (2011). STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17. Cancer Research. 71(10). 3658–3668. 80 indexed citations
7.
Li, Long Shan, Erik A. Bey, Ying Dong, et al.. (2011). Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy. Clinical Cancer Research. 17(2). 275–285. 94 indexed citations
8.
Kapuria, Vaibhav, Luke F. Peterson, Dexing Fang, et al.. (2010). Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Research. 70(22). 9265–9276. 317 indexed citations
9.
Pham, Lan V., Archito T. Tamayo, Changping Li, et al.. (2010). Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo : Therapeutic Implications. Molecular Cancer Therapeutics. 9(7). 2026–2036. 46 indexed citations
10.
Blanco, Elvin, Erik A. Bey, Chalermchai Khemtong, et al.. (2010). β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer Therapy. Cancer Research. 70(10). 3896–3904. 115 indexed citations
11.
Konopleva, Marina, Julie C. Watt, Rooha Contractor, et al.. (2008). Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax). Cancer Research. 68(9). 3413–3420. 215 indexed citations
12.
Zhang, Dongwei, Ashutosh Pal, William G. Bornmann, et al.. (2008). Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics. 7(7). 1846–1850. 69 indexed citations
13.
Qiu, Chen, Mary Katherine Tarrant, Sung Hee Choi, et al.. (2008). Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure. 16(3). 460–467. 144 indexed citations
14.
Fernández, Ariel, Ángela Sanguino, Zhenghong Peng, et al.. (2007). Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target. Cancer Research. 67(9). 4028–4033. 32 indexed citations
15.
Fernández, Ariel, Ángela Sanguino, Zhenghong Peng, et al.. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation. 117(12). 4044–4054. 107 indexed citations
16.
Pedranzini, Laura, Tobias Dechow, Marjan Berishaj, et al.. (2006). Pyridone 6, A Pan-Janus–Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells. Cancer Research. 66(19). 9714–9721. 133 indexed citations
17.
She, Yuhong, Michael J. Soskis, Christopher P. Borella, et al.. (2004). Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. Journal of Clinical Investigation. 114(8). 1107–1116. 83 indexed citations
18.
Yoon, Kyoung Jin P., Christopher L. Morton, William G. Bornmann, et al.. (2003). Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.. PubMed. 2(11). 1171–81. 14 indexed citations
19.
Sirotnak, Francis M., Hans‐Guido Wendel, William G. Bornmann, et al.. (2000). Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.. PubMed. 6(9). 3705–12. 26 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles Dumontet Breakdown of academic impact, for papers by Steven Grant Breakdown of academic impact, for papers by Edward A. Sausville Breakdown of academic impact, for papers by Lorenzo A. Pinna Breakdown of academic impact, for papers by Robert Roskoski Breakdown of academic impact, for papers by Stefan Knapp Breakdown of academic impact, for papers by E. Premkumar Reddy Breakdown of academic impact, for papers by Thomas Meyer Breakdown of academic impact, for papers by Aviv Gazit Breakdown of academic impact, for papers by Giulio Superti‐Furga
Rankless by CCL
2026